08 Feb Propeller signs another major respiratory partner, Novartis
Madison, Wisconsin-based Propeller Health has landed its third major pharma client, paving the way for its add-on sensors and digital health platform to connect with patients and physicians using Novartis Pharma’s chronic obstructive pulmonary disease (COPD) inhalers.
Announced Wednesday, the deal centers around the Breezhaler inhaler, a device used by a portfolio of Novartis COPD treatments.
Propeller has previously collaborated with Boehringer Ingelheim and GlaxoSmithKline, along with U.K.-based Vectura and Aptar Pharma, a leading developer of metered dose inhalers systems.
Sorry, the comment form is closed at this time.